HB 1214 would reduce Virginia's insulin cap from $50 to $35 per 30‑day supply and extend a $35 aggregate cap to diabetes supplies. The subcommittee reported the bill after patient advocates and clinicians testified that reduced cost shares improve adherence and outcomes.

Participants address issues with dosing and traveling with children's medications

Witnesses and members told the House subcommittee that coordinated care cannot work if people lose coverage: several witnesses urged Congress to extend enhanced Affordable Care Act premium tax credits now to avoid millions losing affordable insurance and worsening chronic conditions.

Missouri limits out-of-pocket costs for insulin and epinephrine auto-injectors to $35.

AB 555 mandates health insurers limit insulin cost-sharing to $35 per month.

Bill requires coverage for epinephrine injectors without cost sharing for minors

Senate Bill 447 streamlines prior authorization for chronic conditions in Montana.

SB 964 would allow licensed clinicians to adjust medication dose or frequency up to two clinically appropriate times without a new prior authorization, supporters said this would reduce treatment delays for patients with chronic, complex conditions; health‑plan witnesses raised safety and FDA‑labeling concerns.

SB 242 aims to allow those with end stage renal disease access to Medicare supplements

Health insurance must cover diabetes treatments and limit insulin costs to $25 monthly.

The Assembly Financial Institutions and Insurance Committee amended and released AB3242, which would require health plans to cover continuous glucose monitoring (CGM) systems for glycogen storage disease and sets an effective date of Jan. 1, 2027. Insurers raised implementation and fiscal concerns during testimony.